Cell Biotech Co Stock

Cell Biotech Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Cell Biotech Co (049960.KQ) as of Aug 16, 2026 is 11.89. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 13.85 — a change of -14.12% (lower).

EV/EBIT

11.89

YoY

-14.12%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Cell Biotech Co is 2026 11.89 . EV/EBIT (Enterprise Value to EBIT) of Cell Biotech Co was 2025 13.85 . It decreases by -14.12% lower compared to the previous year.

The Cell Biotech Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
9.71 base
Jan 1, 2019
24.54 base
Jan 1, 2020
48.08 base
Jan 1, 2021
19.49 base
Jan 1, 2022
15.71 base
Jan 1, 2023
39.84 base
Jan 1, 2024
15.76 base
Jan 1, 2025
12.43 base
YEARPRICE-TO-EBIT
2025 12.43
2024 15.76
2023 39.84
2022 15.71
2021 19.49
2020 48.08
2019 24.54
2018 9.71
2017 11.71
2016 17.42
2015 23.50
2014 32.30
2013 16.44
2012 21.48
2011 8.04
2010 5.68
2009 5.70
2008 9.63
2007 21.01
2006 -
Access this data via the Eulerpool API
Get Free API Key

Cell Biotech Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Cell Biotech Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Cell Biotech Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Cell Biotech Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Cell Biotech Co grows earnings faster than its peers.

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

EV/EBIT (Enterprise Value to EBIT) of Cell Biotech Co is 11.89 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Cell Biotech Co changed from 13.85 to 11.89, representing a -14.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Cell Biotech Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Cell Biotech Co